Biologics for Atopic Dermatitis
- PMID: 33012322
- DOI: 10.1016/j.iac.2020.06.004
Biologics for Atopic Dermatitis
Abstract
Atopic dermatitis (AD) is a common chronic inflammatory skin disease that has become a global health problem. The pathophysiology of AD includes both skin barrier and immune abnormalities, with type 2 immune deviation central to several clinical phenotypes and underlying endotypes. Recognition of the persistent nature and systemic aspects of AD provides a rationale for treatment with a biologic. Dupilumab has been approved for patients 6 years of age and older with moderate to severe AD. Monoclonal antibodies are in phase 3 trials and may become part of a precision medicine approach to AD.
Keywords: Atopic dermatitis; Biologics; Dupilumab; Immune dysregulation; Lebrikizumab; Nemolizumab; Omalizumab; Tralokinumab.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest M. Boguniewicz has served as a consultant for Regeneron and Sanofi-Genzyme.
Similar articles
-
Current and Emerging Biologics for Atopic Dermatitis.Immunol Allergy Clin North Am. 2024 Nov;44(4):577-594. doi: 10.1016/j.iac.2024.08.001. Epub 2024 Sep 2. Immunol Allergy Clin North Am. 2024. PMID: 39389711 Review.
-
The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis.Dermatol Clin. 2017 Jul;35(3):327-334. doi: 10.1016/j.det.2017.02.005. Epub 2017 Apr 22. Dermatol Clin. 2017. PMID: 28577802 Review.
-
Dupilumab for the treatment of adolescents with atopic dermatitis.Expert Rev Clin Immunol. 2020 Jul;16(7):641-650. doi: 10.1080/1744666X.2020.1801420. Epub 2020 Aug 13. Expert Rev Clin Immunol. 2020. PMID: 32720530 Review.
-
Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.Exp Dermatol. 2019 Jul;28(7):756-768. doi: 10.1111/exd.13911. Epub 2019 Apr 15. Exp Dermatol. 2019. PMID: 30825336 Free PMC article. Review.
-
IL-13 antagonists in the treatment of atopic dermatitis.Immunotherapy. 2021 Mar;13(4):327-344. doi: 10.2217/imt-2020-0253. Epub 2021 Jan 12. Immunotherapy. 2021. PMID: 33430628 Review.
Cited by
-
Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites.Postepy Dermatol Alergol. 2023 Aug;40(4):542-547. doi: 10.5114/ada.2023.129456. Epub 2023 Jul 14. Postepy Dermatol Alergol. 2023. PMID: 37692262 Free PMC article.
-
An Insight into Biomolecules for the Treatment of Skin Infectious Diseases.Pharmaceutics. 2021 Jul 2;13(7):1012. doi: 10.3390/pharmaceutics13071012. Pharmaceutics. 2021. PMID: 34371704 Free PMC article. Review.
-
Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis.Cells. 2021 Jun 4;10(6):1392. doi: 10.3390/cells10061392. Cells. 2021. PMID: 34200009 Free PMC article. Review.
-
Atopic Dermatitis as a Multifactorial Skin Disorder. Can the Analysis of Pathophysiological Targets Represent the Winning Therapeutic Strategy?Pharmaceuticals (Basel). 2020 Nov 22;13(11):411. doi: 10.3390/ph13110411. Pharmaceuticals (Basel). 2020. PMID: 33266440 Free PMC article. Review.
-
Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis.Pharmaceutics. 2023 Feb 8;15(2):577. doi: 10.3390/pharmaceutics15020577. Pharmaceutics. 2023. PMID: 36839897 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
